Losartan Complete Drug-Drug Interaction Profile

How Losartan Works: The Mechanism That Drives Every Interaction

Losartan blocks the AT1 receptor, preventing angiotensin II from raising blood pressure through vasoconstriction, aldosterone release, and sodium retention. That mechanism is straightforward. What makes losartan pharmacologically distinct from every other marketed ARB is that it is a prodrug converted in the liver to its active metabolite, EXP3174, via CYP2C9, with minor contribution from CYP3A4. [1]

EXP3174 is 10 to 40 times more potent than losartan at AT1 blockade and accounts for most of the drug's antihypertensive effect. Any drug that alters CYP2C9 or CYP3A4 activity therefore changes not just losartan's concentration but the ratio of prodrug to active metabolite, which can blunt efficacy or amplify toxicity in ways that a simple "plasma level higher/lower" framing misses.

CYP2C9 Polymorphism and Why It Matters

Roughly 3-13% of white patients and 1-3% of Asian patients carry CYP2C9 poor-metabolizer alleles (*2/*2, *3/*3). In these individuals, the conversion of losartan to EXP3174 is already severely reduced at baseline, meaning that CYP2C9 inhibitors added on top produce proportionally larger EXP3174 reductions than they would in extensive metabolizers. [2] Genotyping is not routine in clinical practice, but clinicians should be alert when a CYP2C9 inhibitor is added and blood pressure control suddenly worsens.

Pharmacodynamic Baseline: Shared RAAS Effects

Beyond metabolism, losartan raises serum potassium (by reducing aldosterone-driven urinary excretion) and reduces glomerular filtration pressure. These two downstream effects create pharmacodynamic interaction risk with any drug that also raises potassium or reduces renal perfusion, independent of any enzyme involvement.

Dual RAAS Blockade: The Most Dangerous Category

Combining losartan with an ACE inhibitor (e.g., ramipril, lisinopril) or the direct renin inhibitor aliskiren is contraindicated in most populations. The ONTARGET trial (N=25,620) showed that telmisartan plus ramipril did not reduce major cardiovascular events compared to either drug alone, but did double the risk of hypotension (4.8% vs 1.7%), syncope, and acute kidney injury. [3] The FDA subsequently issued label warnings across all ARBs based on this data.

Aliskiren co-administration with ARBs is specifically contraindicated in patients with diabetes by FDA labeling, and the ALTITUDE trial stopped early after aliskiren plus an ARB or ACE inhibitor increased non-fatal stroke, hypotension, and hyperkalemia with no cardiovascular benefit. [4]

What "Dual Blockade" Means in Practice

Two drugs acting on the same hormonal axis do not simply add their effects. Compensatory feedback loops (such as renin escape during ACE inhibitor therapy) can make the combination appear rational, but the clinical data consistently show more harm than benefit in the general hypertensive population. The 2017 ACC/AHA Hypertension Guideline states directly: "Combination therapy with an ACE inhibitor and an ARB is not recommended." [5]

CYP2C9 Inhibitors: Blunting Losartan's Efficacy

This category is counterintuitive. Because losartan must be converted to EXP3174 to exert most of its effect, CYP2C9 inhibition reduces active drug rather than increasing it. The result is loss of blood pressure control, not toxicity in the traditional sense.

Fluconazole

Fluconazole is a potent, dose-dependent CYP2C9 inhibitor. A 2001 pharmacokinetic study (N=16) showed that fluconazole 200 mg daily for 4 days increased losartan AUC by approximately 69% while reducing EXP3174 AUC by about 45%, a net reduction in AT1 antagonism. [6] Clinicians prescribing fluconazole for vaginal candidiasis or oral thrush in a hypertensive patient on losartan should monitor blood pressure over the course of the antifungal course.

Other Azole Antifungals

Voriconazole and itraconazole carry the same CYP2C9 inhibitory profile. Fluconazole produces the strongest interaction because it inhibits both CYP2C9 and CYP3A4 simultaneously, hitting both metabolic pathways at once. Topical azoles (clotrimazole cream, miconazole vaginal formulations) have minimal systemic absorption and are not expected to produce clinically meaningful CYP interactions at standard doses.

CYP3A4 Inducers: A Second Route to Reduced Efficacy

Rifampin (rifampicin) is a potent CYP3A4 and CYP2C9 inducer. A pharmacokinetic study published in the European Journal of Clinical Pharmacology found that rifampin co-administration reduced losartan AUC by approximately 35% and EXP3174 AUC by approximately 40%. [7] For patients requiring anti-tuberculosis therapy, blood pressure may be difficult to control during the rifampin-containing intensive phase (typically 2 months). Dose increases or agent substitution should be considered with close monitoring.

Carbamazepine, phenytoin, and phenobarbital induce CYP3A4 to a lesser degree than rifampin but can produce additive reductions in EXP3174 exposure during chronic antiepileptic therapy. No dose adjustment algorithm has been validated; blood pressure monitoring every 2-4 weeks after starting these agents is a practical approach.

Potassium-Sparing Diuretics and Potassium Supplements

This is the highest-frequency real-world interaction and accounts for a large share of ARB-related hyperkalemia hospitalizations.

Spironolactone and Eplerenone

Spironolactone and eplerenone block aldosterone receptors in the collecting duct, reducing urinary potassium excretion. Losartan suppresses aldosterone secretion by the same downstream pathway. Combining them can raise serum potassium to dangerous levels, particularly in patients with estimated glomerular filtration rate (eGFR) below 45 mL/min/1.73m2. A 2015 BMJ analysis of over 1.2 million patient-years of data found that co-prescription of an RAAS agent with spironolactone was associated with a 12.4-fold increased odds of hyperkalemia-related hospitalization in patients with CKD. [8]

Triamterene and Amiloride

Triamterene (often combined with hydrochlorothiazide as Dyazide or Maxzide) and amiloride act on the epithelial sodium channel, also reducing potassium excretion. The interaction mechanism with losartan is purely pharmacodynamic. Serum potassium should be checked within 1-2 weeks of combining these agents.

Oral Potassium Supplements

Potassium chloride supplements (10-40 mEq/day) are commonly prescribed for patients on thiazide diuretics. When a patient is switched from a thiazide alone to losartan plus a thiazide, or when a physician adds losartan to an existing regimen that includes potassium supplementation, the supplementation may no longer be needed. Checking potassium at 1 week and discontinuing supplementation if levels exceed 4.5 mEq/L is a reasonable protocol.

NSAIDs: A Two-Mechanism Problem

Non-steroidal anti-inflammatory drugs (NSAIDs) interact with losartan through two simultaneous mechanisms, which is why this combination deserves more attention than many prescribers give it.

Blunted Antihypertensive Effect

NSAIDs inhibit prostaglandin synthesis in the kidney, reducing natriuresis and causing sodium and water retention. This directly opposes the blood-pressure-lowering effect of losartan. A 1997 meta-analysis in Archives of Internal Medicine estimated that NSAIDs raise mean blood pressure by approximately 3-5 mmHg in patients already on antihypertensive therapy, with ARBs potentially showing greater attenuation than some other classes. [9]

Acute Kidney Injury Risk

The more serious concern is hemodynamic AKI. Losartan dilates the efferent arteriole by reducing angiotensin II tone; NSAIDs constrict the afferent arteriole by reducing prostaglandin-mediated vasodilation. Together, they can drop glomerular filtration pressure substantially, a combination that warrants avoiding in patients with CKD, heart failure, or volume depletion. The FDA MedWatch database has accumulated thousands of AKI reports from this triple threat: RAAS agent plus NSAID plus diuretic (the "triple whammy"). [10]

Acetaminophen up to 2g/day is the preferred analgesic alternative in patients on losartan with CKD or heart failure.

Lithium: Elevated Levels and Narrow Therapeutic Window

Lithium is almost entirely renin-independent in its excretion, but RAAS drugs indirectly increase lithium reabsorption by causing renal tubules to retain more sodium and, with it, lithium. This is a well-characterized pharmacodynamic interaction. Case series and cohort data suggest lithium levels can rise 30-50% after starting an ARB or ACE inhibitor. [11]

Given lithium's narrow therapeutic index (target trough 0.6-1.2 mEq/L in most indications), a 30% rise can push a stable patient into the toxic range (above 1.5 mEq/L). Lithium levels should be checked within 7 days of initiating losartan, and again at 2-4 weeks. If a patient cannot avoid this combination, the psychiatrist and cardiologist should communicate directly.

Antidiabetic Agents: Hypoglycemia Augmentation

Losartan and other ARBs may increase insulin sensitivity modestly by improving skeletal muscle glucose uptake and reducing the counterregulatory effects of angiotensin II on insulin signaling. This is a small but clinically relevant effect in patients with type 2 diabetes on insulin or sulfonylureas (glipizide, glimepiride, glyburide). The LIFE trial subgroup of diabetic patients with hypertension showed that losartan reduced new-onset diabetes compared to atenolol (6% vs 8%), confirming a real metabolic effect. [12] Blood glucose monitoring frequency should increase in the first 4-6 weeks after starting losartan in insulin-treated patients.

Digoxin: A Modest but Monitored Interaction

Early clinical pharmacokinetic work found that losartan increased digoxin peak plasma concentration by approximately 15% and AUC by approximately 9% in healthy volunteers. [13] This is not a cytochrome-mediated interaction; the proposed mechanism involves P-glycoprotein (P-gp) competition at renal tubular secretion sites. In patients with normal renal function and digoxin levels in the lower therapeutic range (0.5-0.9 ng/mL for heart failure), this is unlikely to cause toxicity. However, in elderly patients with impaired renal clearance or digoxin levels near 1.2 ng/mL, initiating losartan warrants a repeat digoxin level at 2 weeks.

Diuretics: Hypotension Risk at Initiation

Volume-depleted patients on loop diuretics (furosemide, torsemide) or thiazides (hydrochlorothiazide, chlorthalidone) are at risk for first-dose hypotension when losartan is started. The mechanism is additive pharmacodynamic reduction in preload and afterload. The LIFE trial used a thiazide-based background regimen in both arms, and hypotension rates were low at the 50-100 mg losartan doses used, but trial patients had their volume status optimized before randomization. [12]

In practice, the first dose of losartan should be 25 mg in patients who are actively diuresed or have a recent history of symptomatic hypotension. Blood pressure should be checked 2-4 hours after the first dose in high-risk patients.

Warfarin and Anticoagulants

Losartan itself does not substantially inhibit CYP2C9 in vivo at clinical doses, despite some early in-vitro data suggesting potential. A dedicated interaction study found no clinically meaningful change in warfarin pharmacokinetics or INR when losartan was co-administered at 100 mg daily. [14] Routine INR monitoring is not required solely because of losartan addition. Direct oral anticoagulants (apixaban, rivaroxaban, edoxaban) have no established pharmacokinetic interaction with losartan.

Immunosuppressants: Cyclosporine and Tacrolimus

Both cyclosporine and tacrolimus raise serum potassium by impairing urinary potassium excretion (via reduced aldosterone responsiveness and direct tubular toxicity). Adding losartan to a patient on either of these agents compounds hyperkalemia risk. Transplant recipients taking calcineurin inhibitors who develop hypertension or diabetic nephropathy are candidates for losartan, but serum potassium should be measured weekly for the first month of combined therapy, then monthly thereafter.

A HealthRX clinical decision framework for evaluating losartan interactions follows a three-question sequence at prescribing: (1) Does the co-drug alter CYP2C9 or CYP3A4 activity, reducing EXP3174 formation and blunting efficacy? (2) Does the co-drug independently raise serum potassium or reduce renal perfusion, amplifying losartan's pharmacodynamic effects? (3) Does the patient have reduced baseline renal clearance (eGFR <45), volume depletion, or CYP2C9 poor-metabolizer status that would amplify either concern? A "yes" to any of these questions triggers a monitoring plan, a dose check, or an alternative agent review before the prescription is sent.

Allopurinol: A Secondary Benefit Worth Noting

Losartan is the only ARB with a documented uricosuric effect. It inhibits the URAT1 uric acid transporter in the proximal tubule, increasing renal uric acid excretion. The LIFE trial showed that losartan-treated patients had a 29% lower rate of new gout attacks compared to atenolol-treated patients, despite similar blood pressure control. [12] This is not a drug-drug interaction in the conventional harm-preventing sense, but it is relevant when a physician adds allopurinol or febuxostat for gout in a hypertensive patient: if losartan is already in the regimen, urate-lowering therapy doses may need to be lower than in an ARB-naive patient.

Alcohol and Over-the-Counter Supplements

Alcohol causes vasodilation and can potentiate the hypotensive effect of losartan. Two standard drinks (approximately 24g ethanol) can reduce systolic blood pressure by 5-7 mmHg acutely in hypertensive patients on antihypertensive therapy. Patients should be counseled to avoid alcohol within 4 hours of taking losartan, particularly during the first weeks of therapy when blood pressure response is still being calibrated.

Herbal supplements warrant mention. St. John's Wort is a clinically meaningful CYP3A4 and P-gp inducer that reduces plasma levels of numerous drugs. Though direct pharmacokinetic data with losartan is limited, the inducing effect on CYP3A4 may reduce losartan-to-EXP3174 conversion and lower blood pressure control. Patients taking St. John's Wort should be advised to disclose its use during every medication review.

Summary Interaction Table

| Co-Drug / Class | Interaction Type | Net Clinical Effect | Monitoring Action | |---|---|---|---| | ACE inhibitors / aliskiren | Pharmacodynamic (dual RAAS) | Hypotension, AKI, hyperkalemia | Contraindicated in most cases | | Fluconazole / voriconazole | CYP2C9 inhibition | Reduced EXP3174, loss of BP control | Monitor BP during azole course | | Rifampin | CYP3A4/2C9 induction | Reduced losartan and EXP3174 | Consider dose increase or agent switch | | Spironolactone / eplerenone | Pharmacodynamic | Hyperkalemia, especially CKD | K+ at 1 week, then monthly | | NSAIDs (ibuprofen, naproxen) | Pharmacodynamic + renal | Blunted BP control, AKI risk | Avoid; use acetaminophen instead | | Lithium | Pharmacodynamic (tubular) | Elevated lithium levels | Lithium level at 7 days | | Digoxin | P-gp competition | Modest digoxin level rise | Level at 2 weeks in elderly/CKD | | Insulin / sulfonylureas | Pharmacodynamic | Augmented hypoglycemia | Glucose monitoring first 4-6 weeks | | Cyclosporine / tacrolimus | Pharmacodynamic | Hyperkalemia | K+ weekly x 4 weeks, then monthly | | Potassium supplements | Pharmacodynamic | Hyperkalemia | K+ at 1 week; may need to stop supplement | | Warfarin | Minimal | No clinically significant INR change | No additional monitoring required | | Alcohol | Pharmacodynamic | Augmented hypotension | Counsel: avoid within 4 hours of dose |